12:00 AM
 | 
Nov 03, 2014
 |  BC Week In Review  |  Company News  |  Deals

AKTivate Therapeutics, Virax deal

Virax will acquire AKTivate Therapeutics for $300,000 in cash and 134 million shares up front valued at A$1.3 million ($1.2 million) and up to 100 million additional shares valued at A$1 million ($879,400) tied to clinical milestones. Virax gains

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >